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Background: Clinical trials test new ways to prevent, detect, diagnose, or treat diseases. Researchers have
found that minority patients are willing to participate in clinical trials, yet these patients have barriers
which hinder their access to trials.
Methods: To explore African American women's participation in breast cancer clinical trials, eight focus
groups were conducted with breast cancer patients, family members/care givers, religious leaders, and
healthcare providers to gather information on the perspectives and opinions on the topic. The focus
group conversations were transcribed, and transcripts were imported into QSR International's NVivo 10
software. The transcripts were organized into folders based on four categories. The content analysis
performed was based on recordings and notes.
Results: The following themes were generated as a result of conducting these focus groups and gathering
information on the perspectives and opinions about participating in clinical trials, based on the groups
who participated: Promoting participation in research; Personal experience with cancer; Support and
support services; Awareness, knowledge, and experience with clinical trials; Providers' roles in clinical
trials.
Conclusion: The data collected in this study present several actionable themes that, if addressed by in-
dividual researchers and the medical community at large, could increase participation in clinical trials by
African American patients. They also provide a deeper and more nuanced understanding of the factors
inﬂuencing African American patients' decisions around participating in clinical trials.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Disparities impact African American women across the breast
cancer spectrumwith respect to access and utilization of screening
and preventive services, clinical care subsequent to breast cancer
diagnosis, and long-term follow-up care and clinical management
for Black breast cancer survivors [1]. Racial differences in breast
cancer survival can be explained by poorer health of Black patients
at diagnosis, more advanced disease at time of diagnosis, more
severe biological features of the disease, and more co-morbid
conditions [2,3]. The data collected by Silber et al. to determine if
racial disparities in breast cancer survival were attributableedical Center, 4000 Reservoir
.
.M. Swain).
Inc. This is an open access article uprimarily to differences in presentation characteristics at diagnosis
or subsequent treatment provide evidence that Black patients
diagnosedwith breast cancer had previously received less adequate
primary care compared to White counterparts. Also, Blacks were
diagnosed with more advanced disease and with larger tumors [4].
Clinical trials test newways to prevent, detect, diagnose, or treat
diseases. Individuals who take part in cancer clinical trials have an
opportunity to contribute to scientists' knowledge about cancer
and to help in the development of improved cancer treatments.
They also receive state-of-the-art care from cancer experts [5].
Advances in breast cancer prevention, diagnosis, and treatment are
the direct result of patient involvement in therapeutic and non-
therapeutic clinical trials. The success of these trials depends on
enrolling the statistically required number of participants and
keeping them in the study until completion. Despite increases in
the numbers of new clinical research initiatives and trials open tonder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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clinical trial [6]. Poor recruitment to clinical trials leads to delays in
study completion and slows down the approval of more effective
cancer treatments for patients with all stages of cancer [7].
Increasing Black patients' participation in cancer clinical trials is
particularly important because of their lower survival rate. Critical
to the conduct of any clinical trial is identifying the right group of
people to include in the study. Most clinical trials conducted in the
U.S. suffer from a pronounced lack of diversity. And, too often, there
is a lack of appreciation of cultural and genetic factors particular to
African American and other ethnic communities. This diversity gap
can lead to sub-optimal development of new medicines and can
further exacerbate minority health disparities. While African
Americans represent 12% of the total U.S. population, they comprise
just 5% of clinical trial participants [8].
Researchers have found that minority patients are willing to
participate in clinical trials, but that these patients have barriers
which hinder their access [9]. Therefore, further exploration of the
potential barriers and motivating factors in regard to participation
in clinical trials is essential to increasing participation and retention
rates, and ultimately, to reducing disparities in quality healthcare
and treatment options.
The purpose of our focus group study was to explore African
American patients' participation in breast cancer clinical trials. To
accomplish this, we conducted formative data-focused groups to
investigate different thoughts, attitudes, and beliefs associated
with cancer clinical trials from various viewpoints.
2. Methods
Study design. We conducted eight focus groups in 2014 and 2015,
made up of Black patients with breast cancer, patient family
members/caregivers, religious leaders, and healthcare providers
from Washington Cancer Institute (WCI) (52 participants ¼ 12 pa-
tients, 21 faith-based leaders, 11 healthcare providers, 8 family
caregivers).
Eligibility. Participants who met the following eligibility criteria
were appropriate to take part in the study:
 Patient: Self-identiﬁed Black or African American (to include
African, Caribbean, West Indian ancestry, or any other persons
self-identifying as Black); 2) aged 18 years or older with breast
cancer diagnosis, receiving treatment at WCI; 3) ability to
communicate verbally in English, male or female, ability to
comply with all study procedures.
 Family member/caregiver: A family member, spouse, signiﬁcant
other, or caregiver to a patient diagnosed with breast cancer
who is receiving treatment at WCI.
 Provider: Healthcare provider practicing at WCI.
 Religious leader: Religious leader (to include pastor, health
ministry member, deacon, or any other position closely involved
with parishioners) at a church in the District of Columbia
Metropolitan Area.
Recruitment. Fifty nine percent of participants screened for
eligibility participated in the focus groups. Patients were recruited
through medical/oncology clinics and from staff referrals. Re-
cruiters met with patients before or after the oncologist saw them
for an appointment. They introduced and explained Focus on You,
conﬁrmed eligibility, invited participation, conducted the informed
consent process, and obtained written informed consent from
those who wished to participate. Patients were assured that con-
senting to this study would not imply that they were consenting to
a therapeutic clinical trial. Family members/caregivers were
approached as they accompanied their loved ones to theirappointments. Religious leaders were referred by patients and WCI
staff, and were approached about participating in person, via email,
or by telephone. Providers were approached about participating on
site at WCI and via email communication.
Focus group implementation. Prior to conducting the focus
groups, WCI staff (the project leader and research assistant) were
trained in focus group methods and facilitation. The training was
coordinated by an experienced facilitator who conducts qualitative
training with academicians and community members. The patient
and provider focus groups occurred on site at WCI, while the reli-
gious leader focus groups occurred at the respective churches. A
trained moderator facilitated each focus group. Focus groups were
recorded and a note-taker was present to capture hand-written
notes. A moderator who was not employed by the Washington
Cancer Institute conducted both provider focus groups to avoid any
conﬂict of interests and to allow providers to feel comfortable
participating. These focus groups took place at WCI.
The interview guides for each focus group cohort used by the
WCI team were developed during the initial training session. The
guides consisted of prompts/questions to solicit responses from the
groups. An introduction and overview script was developed to
assist the facilitator and moderator in properly introducing the
focus group and cover the purpose, logistics, goals, and ground
rules.
The moderator asked participants a series of questions/probes
using a semi-structured interview guide [10]. The guides were
tailored to each focus group category (See Table 1). Sample ques-
tions included:
 Patients: “What is a clinical trial or clinical research?” and “Do you
think it is important to include Blacks in clinical trials or clinical
research?”
 Providers: “How often do you talk to your patients about clinical
trials or clinical research?” and “Do you think your attitudes/beliefs
about clinical trials play a role in your patients' decision to
participate in research?”
 Family members/caregivers: “In your opinion, what do you think
are some of the advantages and disadvantages of clinical
research?” and “If your family member was asked to participate in
a clinical trial trying to ﬁnd new and better treatment for breast
cancer, would you encourage them participate?”
 Religious leaders: “Do you think you and/or other leaders in the
church have an impact on your members' healthcare choices and
decisions, including participating in clinical research?” and “What
do you think can be done to encourage more Blacks to participate
in clinical research?”
All focus groups were audio recordedwith a digital recorder and
a note-taker was present. The number of participants in each focus
group ranged from 3 to 12 (Table 1). Each focus group lasted be-
tween 60 and 80 min. Refreshments and parking vouchers were
provided. All participants, with the exception of physicians,
received a $25.00 gift card for their participation. The study was
approved by the Georgetown University MedStar Health Research
Institute Institutional Review Board. The demographic character-
istics of the patient participants are displayed in Table 2.
Data analysis. An outside research ﬁrmwas hired to analyze the
focus group data. A conventional qualitative content analysis
approach [11] was used to inductively analyze and identify the
categories/themes that emerged from the focus groups. This is a
bottom-up approach that builds upon the data as opposed to a
deductive coding scheme that is established in advance of the
analysis. The focus group conversations were transcribed, and the
transcripts were imported into QSR International's NVivo 10 soft-
ware. The transcripts were organized into folders based on four
Table 2
Demographic characteristics of breast cancer patient participants.
n ¼ 12
Demographic n (%)
Age (years): median[range] 65 [41e77]
Marital status Never married 3 (25)
Married 3 (25)
Widowed 2 (17)
Separated/divorced 4 (33)
Number of children None 2 (17)
1 or more 10 (83)
Education High School 5 (42)
Some college or technical school 2 (16)
College graduate 5 (42)
Religion faith Baptist 7 (58)
Catholic 1 (8.3)
Lutheran 1 (8.3)
Pentecostal 1 (8.3)
Presbyterian 1 (8.3)
No afﬁliation (none) 1 (8.3)
Household income US$ <40000 6 (50)
40000 6 (50)
Type of insurance Medicaid 4 (33.3)
Medicare 4 (33.3)
Private 4 (33.3)
Family history of any cancer Yes 10 (83)
No 2 (17)
Stage of cancer I 6 (50)
II 3 (25)
III 1 (8)
IV 2 (17)
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sentence of the focus group conversations was reviewed. The
relevant text was coded with one or more codes as necessary. Key
concepts, thoughts, ideas, and events were coded using partici-
pants' words to establish the codes. Codes were added or modiﬁed
as necessary as new meanings emerged [13]. To assess coding
consistency, codes and their assignment to text were checked and
rechecked. Using a constant comparison method [12], codes were
compared and queried in NVivo to determine overall reoccurring
themes and subthemes that emerged from all of the groups.
Representative quotes were selected to support the themes and
subthemes. To ensure trustworthiness of the data, conﬁrmability
was performed by two doctoral-level researchers, who audited the
data and ensured internal consistency of the codes, themes, and
subthemes [14].
3. Results
Five main themes and 24 subthemes (Table 3) emerged from the
data. These themes include: promoting participation in research;
personal experiences with cancer; support and support services;
awareness, knowledge, and experience with clinical trials; and
providers' roles in clinical trials.
4. Discussion
The aim of our study was to gather information on the per-
spectives and opinions about participating in clinical trials by
different cohorts of stakeholders such as breast cancer patients,
their family members/caregivers, religious leaders, and healthcare
providers. The objective was for the information we received from
the focus groups to help us improve our approach to clinical trial
enrollment among African American patients at MedStar Wash-
ington Hospital Center, Washington Cancer Institute.
The history of medical research and experimentation and the
African American community is complicated and fraught with both
neglect and abuse [15]. With this historical background, it is not
surprising that exploration into the willingness of African Ameri-
cans to participate in medical research is both plentiful and unclear
in its ﬁndings. In past studies, research indicates that African
Americans are signiﬁcantly less willing to participate in medical
research than other populations [16e19]. On the other hand,
despite underrepresentation in clinical trials, recent studies suggest
that African Americans, more than any other racial and ethnic
group, have interest in participating in research.” [20e25] Our
study's ﬁndings are signiﬁcant in the ability to shed some light on
these conﬂicting ﬁndings.
An awareness of the complicated history is evident in some of
the answers, particularly to theoretical participation. For example,
“I'm glad the question was asked because it shows, I hope, a genuine
interest in including a demographic that's typically excluded in a lot of
settings” suggests awareness of exclusion from studies, while “They
gonna have separate units. You just watch. They gonna have separate
units” suggests concern about how African Americans are typically
included. Similarly, participants discussed concerns about howTable 1
Categories of participants.
Group Description
Faith Group Participants were faith-based leaders
Family and Caregivers Participants were either family members of or caregiv
Patients Participants were undergoing treatment for breast can
Providers Participants were healthcare providers at WCI
a Focus group 1 is FG 1, focus group 2 is FG 2.they are perceived by the medical community: “I think we tend to
think that the medical professional, in general, think that we're
expendable, so they're willing to use us as quote unquote the guinea
pig for somethin’ better.” There is also an awareness of the disparities
in how cancer impacts African Americans: “… yeah, I think on paper
we do need to be involved because so many diseases hit African
Americans so much harder.” In discussing how to encourage
participation, trust is a major theme that came up in multiple ways.
Trust in one's provider (“Anything my doctor would ask me to do, I
would try”), and needing medical providers to prove themsel-
vesdand by extension the trialdtrustworthy (“It's really on the
medical professionals, too. They have to build a level of trust that when
they recommend something that you trust their judgment and say,
okay, you haven't steered me wrong yet”), emerged as essential. This
ﬁts with the literature, which suggests that successful recruitment
of minority participants to clinical trials needs to begin with efforts
to develop trusting relationships between the minority community
and the research institution.” [26].
This study sought to illuminate the decision-making process by
asking Black cancer patients both about their feelings about theo-
retical participation (“Do you think it is important to include Blacks in
clinical trials or clinical research?”) and their personal barriers to,
and likelihood to participate in, clinical trials. Furthermore, it
explored their knowledge and experiences with trials and the
conversations they had with their providers. By asking theirNumber of participants in each focus group
aFG 1 n ¼ 9, FG 2 n ¼ 12
ers of breast cancer patients FG 1 n ¼ 3, FG 2 n ¼ 5
cer FG 1 n ¼ 6, FG 2 n ¼ 6
FG 1 n ¼ 7, FG 2 n ¼ 4
Table 3
Themes and subthemes.
Themes/subthemes Description Examples of responses
Theme:
Promoting participation in
research
Participants discussed African Americans' participation in clinical
research and how to promote their participation in research. Several
topics were addressed by participants, including: the importance of
including African Americans in research, ways to encourage African
Americans to participate, participants' willingness to participate or
encourage others to participate, family and friends' roles and
opinions about clinical trials, church leaders' involvement in clinical
trial participation, and using the church to educate and facilitate
access to participants.
Subtheme:
Importance of including
African Americans in
research
a. Participants felt it was important when collecting research and
data to include all races, socio-economic groups, genders, and ages.
b. A number of participants expressed that including African
Americans in clinical research can help to identify how different
procedures affect African Americans versus other [racial] groups.
c. Some participants mentioned that Blacks are treated differently
than Whites when it comes to clinical research.
d. Another participant shared that she thought there would be
separate units for Blacks versus Whites in the future (*units refers to
departments where hospital rooms are housed).
e. Some participants shared that including African Americans in
clinical research is important because African Americans are heavily
impacted by diseases.
a. “I think it is important to include African Americans in the research
as well as many other things and not just African Americans, but
seniors.”
b. “I think given the African American disposition as well as even
unique particularities, it would behoove us to participate so that we
might even understand how particular procedures might impact us
juxtaposed to other populations.”
c. “… Black people get cancer, too, so yeah. Everything's not gonna
work like what works for Caucasians, or Asians, or Latinos. That don't
mean it's gonna necessarily work for African-American(s).”
“I'm glad the question was asked because it shows, I hope, a genuine
interest in including a demographic that's typically excluded in a lot
of settings.”
d. “They gonna have separate units. You just watch. They gonna have
separate units.”
e. “I think we need to be taken more into consideration because we
are so deeply affected by these disorders.”
“… Yeah, I think on paper we do need to be involved because so
many diseases hit African Americans so much harder.”
Subtheme:
Ways to encourage African
Americans to participate in
clinical research
a. Participants shared a number of different ideas for encouraging
African Americans to participate in clinical research. One idea was to
have them talk to other participants about their experience.
b. Participants discussed having physicians talk to their patients and
educate them as a way to encourage African Americans to
participate.
c. Some participants mentioned using ﬂyers and literature to inform
and recruit participants. They mentioned leaving the ﬂyers in social
workers' ofﬁces, waiting rooms, elevators, hospitals, and churches.
d. Some participants thought that the church providing ﬂyers,
different types of information, or even a schedule of different events
related to clinical research could help increase clinical trial
participation.
e. In addition, participants discussed the availability of information.
a. “… If possible, speak with patients about their experience and
whether or not they think it's worth it, whether or not they feel they
made a mistake and wish they could do it over.”
“Okay, if like my friend, for instance, she is participatin’ in the
research. If she knew someone, maybe she could tell them about the
trial that she's going through right now.”
b. “I think also it would be important to key in on the physicians. I
know the different institutes or hospitals have their medical staff and
especially if they're connected with the research oriented institution
or university institution, let them know to talk to their patients, and
especially in this area where there are such a high number of African
Americans.
c. “I guess if I was looking for something I know theremight be things
visibly displayed on boards, like bulletin boards or something, some
upcoming events having clinical research, like a ﬂier like that.
“… Putting ﬂyers in the social worker's ofﬁce” would be a way to
encourage participation.
d. “If we had some ﬂyers or a lot of different type of informationdwe
have an administrative desk in our church. They put a lot of literature
and things out on that desk. If we had something we could put out
there and people will get it and read it, and that's one way of being
familiar with some of the things that's going on.”
e. “I just said I think it's a good idea if you could have more
information available to us and for more of the groups in the church
to get together to have something like this.”
Subtheme:
Willingness to participate or
encourage others to
participate
a. Participants were asked if they were willing to encourage others to
participate in clinical research. A number of them responded that
they would encourage others and that they themselves would
consider participating in clinical research.
b. Some participants expressed that they would need to trust the
doctor in order to encourage others to participate or participate
themselves.
c. Patient understanding of the clinical trial along with any potential
side effects was mentioned as an important idea in participants'
decision to either participate or encourage others to participate.
d. Some participants mentioned that it is important that clinical
research accounts for their other co-morbid health conditions.
e. Participants discussed trying to understand and digest all of the
information they are provided about the clinical trial.
a. “If it was going to ﬁnd more ways to treat cancer or to come up
with new medicine or new techniques or better techniques, I would
encourage them.”
b. “If it was me, I would participate because I would want to stay here
longer. Anything my doctor would ask me to do, I would try…”
“It's really on the medical professionals, too. They have to build a
level of trust that when they recommend something, that you trust
their judgment and say, okay, you haven't steered me wrong yet.”
c. “Who is doing the research? What's entailed? I don't know if I
would get into the speciﬁcs of what drugs, but I guess I'd try to get an
understanding of their understanding of what they're being asked to
participate in.”
“I think, well, the ﬁrst thing is to wantdparticipate is to understand
what kind of the research is, what it means.”
d. “Then I have to incorporate my other health issues. Okay, I have
ulcerative colitis. How is that gonna deal with my ulcerative colitis?”
“… The treatment which we're talkin’ about to help someone else,
might counteract with something else that I'm taking. I don't wanna
make matters worse tryin’ to make matters better.”
e. “They keep on, you know? It's a lotta stuff, the detail.”
(continued on next page)
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Table 3 (continued )
Themes/subthemes Description Examples of responses
“They give you the information, because even then she would say,
‘There's certain things that you can't have. You couldn't have been on
this or certain amount of time you couldn't have been on that.’ Like
you said, there's a lot of criteria that goes into it.”
Subtheme:
Family and friends' roles and
opinions about clinical
trials
a. Most of the participants indicated that family members and/or
friends' opinions were important to them in considering their
participation in a clinical trial.
a. “I think yes. My opinion will help her. If I wanted her to try it out or
something she would. She would go with it. I feel like that.”
“… [t]hen she'll just come to me and ask my opinion about it. If I'm
not too iffy about it or I don't feel comfortable with it then she starts
to get second thoughts.”
Subtheme:
Church leaders' involvement
in clinical trial participation
a. Participants discussed their thoughts on the role that church
leaders play in promoting African American participation in clinical
trials.
b. Church leaders shared that they can encourage individual church
members who ask for their input regarding their health, but do not
necessarily inﬂuence the entire congregation.
c. Church leaders shared that it is their role to support the choices
made by congregation members.
d. A couple of participants spoke about the importance of keeping the
congregation and church leadership aware of what was going on
with respect to illnesses.
e. Another participant shared that she believed the church leadership
would pray for a congregation member if that member approached
him or her regarding a health-related condition.
a. “I can say that the leadership has had some inﬂuence on the
waydon my healthcare and the way that I approach it.”
b. “I think that I probably have a minimal impact congregation-wide.
There are members who approach me about their health challenge
and how it's gonna be treated. They are often open to any input that I
might have. Yes, I would say for those persons yes there's great
inﬂuence.”
c. “More often than not, I think most persons end up doing what they
have thought to do and then I lend my support if they go a different
way than I would suggest, because that's my role is to support them
in whatever decision they make.”
d. “It is important that you keep your congregation or your leaders
involved into what's going on with you and your family. Because if
you don't tell us, we don't know.”
e. “I think if one of the members should come to our leader with
something like that and ask him or the congregation to pray for
them, it would be well welcomed.”
Subtheme: Using the church
to educate and facilitate
access to participants
a. Participants shared that they thought using the church to increase
efforts in educating patients and recruiting participants for clinical
research was a good idea.
a. “The church as an institution has access to large numbers of people.
I think that's a forum for getting sort of the message out.”
“I think it's imperative almost to encourage not only that [they] want
to participate, but just to becomemore educated and informed about
the many ways in which a person can ﬁnd, address in a holistic way.”
Theme:
Personal experiences with
cancer
During the focus group sessions, participants shared their personal
experiences with cancer. Those experiences were either something
they themselves experienced or something someone close to them
had experienced. Participants discussed topics including: patient
experiences with cancer, thoughts of suicide, importance of faith and
God, not discussing cancer, and having a family member with cancer.
Subtheme:
Patient experiences with
cancer
a. Participants described how they ﬁrst found out they had cancer
and their experience in living through treatment.
“dWhen they ﬁrst discovered the mass and I was at thedI was just
getting’ a mammogram.”
“When I initially was told, it was like I instantly cried. I prayed on it.
When I went to the doctor, and the ﬁrst thing I said is, “So what's
next?” Because it's already been out there. I have breast cancer.
[That's] not something that oh, we made a mistake. No, it's there.”
“Cuz I've been through it, myself. I had the high dose of it and it made
me not walk. It threw me off my legs, and I've been in and out the
hospital, which you all know.”
Subtheme:
Thoughts of suicide
a. Some participants shared that their experience with cancer left
them with thoughts of suicide.
a. “Every day I was cryin’, say like, “Oh Lord, why me? Why me,
Lord?” All the time. I just wanted to give up and all these bad
thoughts just goin’ through my mind. I felt like I wanted to commit
suicide, you know? I just wanted to jump offd”
“[I] got to the point where I realized I did notdI mean I hate to say it
out loud cuz it sounds horrible, but I had got to the point where I
didn't wanna live anymore.”
Subtheme:
Importance of faith and God
a. Many participants talked about the importance of faith and God
when going through the cancer experience. They shared that they
relinquished their fate and put their lives in God's hands.
b. Another participant shared thoughts about the power of prayer
from a group.
a. “Because I feel that you put it in God's hands and let it go. Let Him
take care of it.”
“I was on death bed, but the medicine that they gave me and stuff,
and people like y'all that helpedme through it, and my family helped
me through it and prayed for me.”
b. I have a very strong support group of people that I know that's
prayin’ for me.”
Subtheme:
Not discuss cancer
a. Some participants mentioned the stigma around talking about
cancer. They noted that African Americans in particular do not want
to discuss their experiences with cancer.
a. “I think a lot of folks are still scared to talk about it. It's just kinda
like, Yeah, I had it. I'm cured. I don't wanna talk about it anymore.”
“Even though the church is full of cancer survivors, nobody's talkin’
about it.”
“We just get that way, ‘cause when I'm dealing with my brother and
with his bone cancer and my niece and my sister and all the different
cancers, but we don't talk about it too much. People gotta hide it.
Back in the days, we didn't know anything about cancer. It was a sore,
they wouldn't say anything.”
Subtheme:
Family members with cancer
a. Many participants discussed living through the cancer experience
with their family members.
One participant discussed taking care of her mother while she
underwent chemotherapy treatments.
a. “What I went through with mymom for 14 weeks, waking up 3:00
in the morning. She screaming, yelling hard. She falls out the bed. I
put her [bathroom] in her bedroom. She couldn't make it there. She
fall. My buddy who lived with us, we be waking up, picking her up. I
kept thinking about the medicine. Something wasn't interacting.
Both of us are diabetic. She taking chemo, too.”
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Table 3 (continued )
Themes/subthemes Description Examples of responses
b. Another participant noted that cancer runs in her family. She
experienced several family members going through cancer
treatment.
b. “… Half of my family has cancer. It runs in the family, from
generation on to now. I had a cousin that was eight years old that had
brain cancer. I watched, from growin’ up, howmy family got sick and
what they went through and stuff like that. Back then, they didn't
have themedicine like they have now. I had [an] aunt, a favorite aunt
that had breast cancer. She was in her 70s, I think, 74 years old and
they took one breast. She got real sick. She went through all these
tests and stuff. She couldn't take it, the medicine and stuff.”
Theme:
Support and support
services
Participants discussed their sources of support, including family
support, support from friends, support services, and support from
the church.
Subtheme:
Family support
a. When going through cancer, support from a family is important.
b. Another participant talked about how her family helped support
her through research.
“a. “In April I found out my husband had cancer. That wasn't a [good
feeling], but I had support from my sisters.”
b. “Both my daughters, when they found out that I had breast cancer,
they went online and searched. They told me, they say, “Mom, hey,
it's your body. You need to learn what's goin’ through your body and
about your body, because that's your body. We can't tell you what to
do, but we're here for you to support you.” They ‘ve been there.”
Subtheme:
Support from friends
a. Many participants mentioned the importance of support from
friends.
b. Another participant emphasized the importance of not going
through cancer alone.
a. “Also, I have a very good support system. I have a friend who had
stage four cancer. She had the surgery, and that was about ten years
ago. Then two years ago it returned, the tumors and all that. She was
very supportive, and we talk all the time.”
b. “It was, like you said, the family, the friends, the support group
means a lot when you're goin’ through this. When you're goin’
through it, it means so much. I tell anybody, you just cannot do this
by yourself.”
Subtheme:
Support services
a. Participants discussed the importance of taking part in support
services such as sessions on how to care for your skin, wig options, or
home remedies.
b. Other participants talked about sessions involving scarf tying and
nail painting.
a. “I remember one woman introducing some type of program to
help hydrate the skin for a nominal fee, extremely nominal, and then
there was another option regarding limited wig options.”
b. “There was a scarf tying. They also had nail painting for when your
nails become dark because of chemo.”
Subtheme:
Support from the church
a. Participants shared that the church and church members provide
support for patients going through cancer and clinical research.
b. Another participant echoed the importance of supporting
congregation members.
a. “That's part of our responsibility to be of great support to them in
our faith and being into supporting our members through any
situation, especially when they're going through cancer, how they're
feeling. When they're just going through, we ﬁx meals for ‘em or
different things to take them to their appointments and stuff like
that. I think we do play a major role when someone is going through
a time with cancer.”
b. “I think it's important for the community to rally around those
who are given a diagnosis wanting not only medical advice, but
spiritual direction in the process.”
Theme:
Awareness, knowledge, and
experience with clinical
trials
Awareness of, knowledge, and experience with clinical trials varied
across participants. Participants discussed topics including: caregiver
awareness, knowledge about clinical trials, and experience with
clinical trials.
Subtheme:
Caregiver awareness
a. Family members and caregiver participants shared that they are
aware of clinical research because they have seen it advertised in
various places such as television, billboards, pamphlets, and the
newspaper.
b. Other participants mentioned seeing posters or information in the
hospital.
c. Some family members or caregivers were not aware or did not
recall that their loved one was involved in a clinical trial.
a. “Yeah, I've seen in the paper or on the train that have billboards,
some talking about clinical research going on.”
b. “I don't come over here too often, but when I do I may have seen a
poster or something talking about it maybe once or twice. It's not
every time I come I see something.”
“As far as for the research I come up here almost three times a week
with my mom. I'm always peeking at one of the pamphlets or
something and just reading it. Maybe I'm passing time or whatever,
but I'll read it.”
c. “She never toldme nothing about the research, but I know she here
all the time. She's going through something with that. I don't know. I
guess she okay with it. I don't know. I'm not sure.”
“I know she's always into something here. It might have been
something that she might have spoken about. Off the top of my head
I can't be too sure.”
Subtheme:
Knowledge about clinical
trials
a. Participants shared what they knew about clinical research and
trials and their thoughts about them. Some participants mentioned
that clinical research helps not only the people participating in the
trials but others as well.
b. Some participants indicated that African Americans think that
White people receive better quality healthcare and treatments.
c. A few participants mentioned that they thought clinical research
involved being a guinea pig.
d. Many participants shared that there is a mistrust regarding clinical
research and trials in the African American community based on
history and abuse that occurred.
a. “A lot of times these things, although we're looking for something
to help ourselves, it's not just for us. It's for those that's coming after
us because if it works, then it can be distributed to the other
patients.”
“I thought, well, this may help someone else, and it's helped me
when I researched the treatment that I wanted to be involved with.”
b. “I thinkdmost African American people have a tendency to think
thatdespecially the White race, Caucasiansdthat they are always
given better healthcare, better quality healthcare.”
“That's how I felt when I came here, and I don[t] see that manyWhite
people sittin’ upstairs. Askin’, well, where are they goin’? They're
gettin’ better treatment than I am?”
(continued on next page)
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Table 3 (continued )
Themes/subthemes Description Examples of responses
c. “My family member was not on board with participating in the
study, primarily for the reason that we mentioned earlier in the
discussion. They felt like they were being a guinea pig.”
“I think we tend to think that the medical professional, in general,
think that we're expendable, so they're willing to use us as quote on
quote the guinea pig for somethin’ better.”
d. “I would probably have to think of the distrust that folk in African
American community have when you have studies such as the
Tuskegee syphilis process that went on for generations, for decades.”
“[e]venwhen you talk of whether the procedure is ethical or whether
the organization or governmental agency is reputable, history might
not always be favorable to both, as it relates to Blacks.”
Subtheme:
Experience with clinical
research
a. Most participants have family members or friends who are
participating or have participated in clinical research.
b. Some participants that had friends in clinical trials reported
favorable outcomes.
a. “I had a brother that went through clinical trial at John[s] Hopkins.
For him, it turned out to be very successful.”
“… I have a brother that stayed in clinical research, because he had
Crohn's disease. He learned a lot from that.”
b. “Well, I know because I have a friend right now that's in clinical
trials. I know it has given her, her life back because when she came
here, I mean, she was really down.”
Theme:
Providers' roles in clinical
trials
Providers play an important role in encouraging participation in
clinical research. In this section, participants described their
thoughts about clinical trials, knowledge about available trials,
barriers to clinical trial participation, communication with patients
about clinical trials, research coordinators' roles in supporting
physicians, and ways to approach patients about clinical trials.
Subtheme:
Thoughts about clinical trials
a. Provider participants shared that if they believe in the trial and
understand the aims of the trial, it is easier to discuss with patients.
b. Another provider participant offered that it is also easier to get
patient buy-in when the provider believes in the trial.
c. Although some may feel the protocol designs are very rigid, the
providers noted that the rigidity is there to protect patients because
the trial may not work.
d. As one participant shared, sometimes a patient may want to
participate but the protocols exclude them.
e. Patients participating in clinical trials sometimes have other
medical issues. Several provider participants shared that having
clinical trials speciﬁcally designed to handle these co-morbidities
would be best.
a. “I think that if I believe the trial, I think it's much easier to pass
along the passion or the interest that I have. If I believe and if I fully
understand the trial. Rather than if it's something that I don't think
that it’s a good idea, probably if it's a not a good idea I will not even
remember.”
b. “We think it's a very good trial. We think both arms are okay. If you
got either one and that would be good for you. If we can say things
like that, you're gonna get a lot more buy-in from patients.”
c. “Some of the rigidity is to protect the patients. Cuz they don't know
if it's gonna work or not.”
“I agree with them being rigid because it gives you an algorithm that
it has to be safe for the patient.”
“To gather appropriate data, more rigid protocols are necessary: I
think they are rigid and I think that's good because otherwise, you
can't systematically evaluate the data.”
d. “It's not that they just don't wanna do it; we can't get ‘em on it.”
e. “Number one, we have a large HIV population, so we don't see
enough trials enrolling for HIV.”
“[t]he HIV Consortium has trials that they use for patients with HIV
and things like that. I don't think there should be a looser inclusion
criteria, but maybe trials speciﬁcally designed for those groups.”
Subtheme:
Knowledge about available
trials
a. In order to talk with patients about trials, the providers noted the
need to know what trials are available. Most provider participants
mentioned that they attend weekly meetings to learn about what
trials are available.
b. In addition to talking about which trials are available or are about
to open, the providers also shared that they talk about which patients
might be eligible for those trials.
a. “Every Tuesday… It's just wemeet with the research… nurses, the
teams, and go through what trials are sort of in the queue to open…”
“We have weekly research meetings and we talk about our open
trials.”
b. “Tuesdays is our research meeting where we go through all our
protocols and prospective outpatients and accruals.”
Subtheme:
Barriers to clinical trial
participation
a. Provider participants discussed some of the barriers they face
when approaching patients about clinical trials and research. A
barrier mentioned by most of the providers was eligibility.
b. In addition to eligibility as a barrier, participants discussed needing
more hands to help with screening and coordinating the research.
c. Along with needing additional help, provider participants talked
about the amount of time it takes to discuss the details about the trial
versus the amount of time they actually get to talk to a patient.
d. Another participant shared the challenge of having the patients
meet with a researcher in the time allotted for their appointment.
a. “… Because I'm thinking about trials outside of the surgical realm,
and so the major barrier is the eligibility.”
“… Just making sure that they're eligible for the trials.”
b. “You need more hands, and this is a time in health care that there
are no more hands.”
“But you need the ancillary support in order to get all that set up
because we have nothing right now to help us.”
c. “The major barrier, I guess time is also because the visits are very
quick. We don't necessarily have the time to delve into all of the
particulars about the study, but we try to at least introduce the
concept and tell ‘em that someone will be approaching them about
these things and try to make them feel like they're a partner in the
care and that this is something they have to give.”
d. “Well, part of it too is again goes back to the patient's time, but
then to also allow them to speak to the research person. That you
don't want the visit to seem rushed, but if you have already talked
about what you're talking about; they've already taken off work or
they've arranged for their visit, their transportation to get here. You
don't want ‘em to have to come back for another visit to speak, but
yet you don't want it to be a rushed visit with research.”
a. “I always say study instead of trial. I try to say study with my own
patients.”
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Themes/subthemes Description Examples of responses
Subtheme:
Communication with patients
about clinical trials
a. When communicating or explaining clinical trials to patients, most
providers shared that they try to avoid using the term “trial” and use
“study” or “research study” instead.
b. Participants also talked about discussing non-therapeutic clinical
trials with their patients.
b. “Those seem to be the easiest ones [to discuss].”
Subtheme:
Research coordinators' roles
in supporting physicians
a. The support mechanisms that the providers have to help them
approach or talk to patients about clinical research are the research
coordinators. A participant noted that the research coordinators have
the time to talk with the patients.
a. “I think that's the big one because they can take the time to talk
about and make schedules for patients and listen to their
complaints.”
Subtheme:
Ways to approach patients
about clinical trials
a. One way to improve the ability to approach patients about clinical
trials is to provide reimbursement or incentives for providers who
spend time with those patients discussing the trials or enrolling
them in the study. Currently, counseling a patient about trial
participation is not reimbursable time.
b. Another participant mentioned an incentive for enrolling patients.
c. Participants shared that having more people to assist is a way to
help the providers approach patients.
d. Other participants noted that having the physician involved is a
better way to approach patients and leads to higher participation.
a. “I mean counseling someone for a trial it's not like a reimbursable
event.”
b. “… Can't it be transforming our views, like the number of patients
that the physician enrolls to a clinical trial per year that would be a
type of incentive.”
c. “More people to help and not [doing] everythingdit has to be a
team approach. It has to be. You might have one or two people
[being] very good, but if there's no other members, the team will not
work.”
d. “I mean there's plenty of studies that show the rate of involvement
is much higher when the physician speaks to them ﬁrst.”
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providersdthe study also looked at the larger context for that de-
cision-making.
Supporting informed decision-making can be one way of
establishing trust and respect in a relationship, and there was a lot
of interest in being informed, feeling that education and support
were important, as compared to pressure or persuasion. For
example, “I think, well, the ﬁrst thing is to wantdparticipate is to
understand what kind of research [it] is, what it means.” This is
important even with the awareness of how very much information
is involved with cancer treatment (“It's a lotta stuff, the detail”). Both
patients and their caregivers highlightedword of mouth as away to
establish comfort with a speciﬁc trial (“Okay, if like my friend, for
instance, she is participatin’ in the research. If she knew someone,
maybe she could tell them about the trial that she's going through right
now”). Participants with family members or friends who had had
positive experiences with trials seemed to carry that positive
impression (“I had a brother that went through clinical trial at Johns
Hopkins. For him, it turned out to be very successful”).
The strategy of working with religious leaders to establish trust
was also explored. One-on-one conversations (“I think that I prob-
ably have a minimal impact congregation-wide. There are members
who approach me about their health challenge and how it's gonna be
treated. They are often open to any input that I might have. Yes, I would
say for those persons yes there's great inﬂuence.); unconditional
support regardless of whether the decision is to participate or not
(“More often than not, I think most persons end up doing what they
have thought to do and then I lend my support if they go a different
way than I would suggest, because that's my role is to support them in
whatever decision they make”); and literature in its appropriate
location in the community such as on bulletin boards (“We have an
administrative desk in our church. They put a lot of literature and
things out on that desk”) were important points that were brought
up.
Once trust is established, another area of concern is that of
practical commitment to participate. How much time would be
involved? Will being assigned to the control still be a good option
for the patient (“If you got [randomized to] either one and that would
be good for you. If we can say things like that, you're gonna get a lot
more buy-in from patients”)? This in particular echoes, and deepens
our understanding of, other research suggesting that the presence
of a no-treatment control or placebo control is inversely correlated
with participation [27].For providers, there was a strong desire for more support. They
felt they needed to have more information about studies before
they could promote participation in them (“I think that if I believe
the trial, I think it's much easier to pass along the passion or the in-
terest that I have. If I believe and if I fully understand the trial. Rather
than if it's something that I don't think that it’s a good idea, probably if
it's a not a good idea I will not even remember”). They indicated they
needed more time with patients to cover their health appointment
needs and the study recruitment communication needs (“The major
barrier, I guess time is also because the visits are very quick”), and/or
more staff to address the study recruitment needs (“You need more
hands, and this is a time in health care that there are no more hands”).
All of these practical and actionable points provide both depth
and instruction to the clinical research community in how to
engage African American communities with regard to recruitment
and retention. They also build upon the research study where we
developed a culturally targeted video designed to impact six spe-
ciﬁc attitudes of African American cancer patients toward thera-
peutic trials and measured intent to enroll [28].4.1. Strengths and limitations
A major strength of this study is that it incorporated not only
patients, but also key stakeholders who have the ability to inﬂuence
patients' decisions to participate in clinical research and shape how
physicians and researchers approach patients. It is important to
gain insight from family members/caregivers, providers, and reli-
gious leaders because in our experience at WCI and as studies have
shown, these have been some of themain dissenters and skeptics of
therapeutic trials. In a study conducted by Brown et al. [29], par-
ticipants described pressures from family members and feeling
overwhelmed as reasons for declining clinical trial participation. Of
14 participants who discussed the trial decision with a family
member, either during or after the visit, eight stated that family
members directly encouraged them to decline participation; three
stated that such advice was indirect. Reasons for this included
feeling that the trial was too dangerous and they did not want their
family member to be a research “guinea pig.”
Some study limitations should also be considered. Our sample
consisted of patients, family/caregivers, providers, and religious
leaders only afﬁliated with WCI, so the results cannot be general-
ized to those outside of this community. Also, all of our patient
participants were female, as there were no eligible African
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Furthermore, religious leaders were not required to personally have
or know anyone with breast cancer, which could have limited their
ability to fully sympathize and understand the journey that breast
cancer patients embark upon from diagnosis to treatment.
5. Conclusion
Our study aimed to explore African American participation in
breast cancer clinical trials, particularly with an eye toward facili-
tating such participation. Through positive experiences in building
trust, word of mouth, increased support of informed decision-
making, and supporting providers to initiate conversations about
trials, there is the potential to increase participation in clinical
trials. The data collected give a deeper and more nuanced under-
standing to the sometimes conﬂicting information collected on this
complex topic.
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